Hit Tumors* Hard With TheraSphere
TheraSphere receives FDA Approval!
After 20 years as a humanitarian exemption device (HDE), the FDA grants TheraSphere pre-market approval, making TheraSphere the only Y-90 therapy indicated for HCC. The FDA has also granted Breakthrough Device designation for TheraSphere treatment for patients with glioblastoma.†
†TheraSphere has not been approved for treatment of patients with glioblastoma
The EPOCH Trial
A Phase III Clinical Trial Evaluating TheraSphere™ in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy.
CAUTION: In the US, Therasphere is under an investigational device exemption for treatment of patients with metastatic colorectal cancer. The safety and effectiveness for this treatment has not been established.
Your patients are fighting for more than their survival. They’re fighting for their quality of life. TheraSphere is uniquely able to help you strike first on both fronts.
Glass Matters With Y-90
1. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y-90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatology. 2017 Dec 1.
*Refers to HCC or associated tumors